PTH(1–84) Is Associated With Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy

Context: In hypoparathyroidism, quality of life (QOL) is compromised as compared to normal subjects. We previously reported our results showing an association with recombinant human PTH(1–84) therapy in hypoparathyroidism and improvement in QOL measures for 1 year. Objective: We tested the hypothesis that PTH(1–84) therapy in hypoparathyroidism through 5 years would be associated with continued improvement in QOL measures. Design: Sixty-nine hypoparathyroid subjects received open-label PTH(1–84). Before and during therapy, subjects completed the RAND 36-Item Short Form (SF-36) Health Survey, a measure of health-related QOL covering eight domains of physical and mental health. Results: At baseline, subjects scored significantly lower than the normative reference range in all 8 domains (T-scores −1.4 to −0.9; P < .001 for all). With PTH therapy, intention-to-treat analysis showed significant improvement in the overall score at 2 months that persisted through 5 years (386 ± 19 to 482 ± 25; P < .0001). The me...